Advertisement
Clinical MedicineIn-Press PreviewOncology Open Access | 10.1172/JCI185408
1Department of Nuclear Medicine and Minnan PET Center, Xiamen University, Xiamen, China
2Key Laboratory of Biomacromolecules, Chinese Academy of Sciences, Beijing, China
3Department of Medical Oncology, Xiamen University, Xiamen, China
4Department of Neurosurgery and Department of Neuroscience, Xiamen University, Xiamen, China
5Medical Isotope Research Center, Peking University, Beijing, China
Find articles by Chen, H. in: JCI | PubMed | Google Scholar
1Department of Nuclear Medicine and Minnan PET Center, Xiamen University, Xiamen, China
2Key Laboratory of Biomacromolecules, Chinese Academy of Sciences, Beijing, China
3Department of Medical Oncology, Xiamen University, Xiamen, China
4Department of Neurosurgery and Department of Neuroscience, Xiamen University, Xiamen, China
5Medical Isotope Research Center, Peking University, Beijing, China
Find articles by Zhao, L. in: JCI | PubMed | Google Scholar
1Department of Nuclear Medicine and Minnan PET Center, Xiamen University, Xiamen, China
2Key Laboratory of Biomacromolecules, Chinese Academy of Sciences, Beijing, China
3Department of Medical Oncology, Xiamen University, Xiamen, China
4Department of Neurosurgery and Department of Neuroscience, Xiamen University, Xiamen, China
5Medical Isotope Research Center, Peking University, Beijing, China
Find articles by Pang, Y. in: JCI | PubMed | Google Scholar
1Department of Nuclear Medicine and Minnan PET Center, Xiamen University, Xiamen, China
2Key Laboratory of Biomacromolecules, Chinese Academy of Sciences, Beijing, China
3Department of Medical Oncology, Xiamen University, Xiamen, China
4Department of Neurosurgery and Department of Neuroscience, Xiamen University, Xiamen, China
5Medical Isotope Research Center, Peking University, Beijing, China
Find articles by Shi, J. in: JCI | PubMed | Google Scholar
1Department of Nuclear Medicine and Minnan PET Center, Xiamen University, Xiamen, China
2Key Laboratory of Biomacromolecules, Chinese Academy of Sciences, Beijing, China
3Department of Medical Oncology, Xiamen University, Xiamen, China
4Department of Neurosurgery and Department of Neuroscience, Xiamen University, Xiamen, China
5Medical Isotope Research Center, Peking University, Beijing, China
Find articles by Gao, H. in: JCI | PubMed | Google Scholar
1Department of Nuclear Medicine and Minnan PET Center, Xiamen University, Xiamen, China
2Key Laboratory of Biomacromolecules, Chinese Academy of Sciences, Beijing, China
3Department of Medical Oncology, Xiamen University, Xiamen, China
4Department of Neurosurgery and Department of Neuroscience, Xiamen University, Xiamen, China
5Medical Isotope Research Center, Peking University, Beijing, China
Find articles by Sun, Y. in: JCI | PubMed | Google Scholar
1Department of Nuclear Medicine and Minnan PET Center, Xiamen University, Xiamen, China
2Key Laboratory of Biomacromolecules, Chinese Academy of Sciences, Beijing, China
3Department of Medical Oncology, Xiamen University, Xiamen, China
4Department of Neurosurgery and Department of Neuroscience, Xiamen University, Xiamen, China
5Medical Isotope Research Center, Peking University, Beijing, China
Find articles by Chen, J. in: JCI | PubMed | Google Scholar
1Department of Nuclear Medicine and Minnan PET Center, Xiamen University, Xiamen, China
2Key Laboratory of Biomacromolecules, Chinese Academy of Sciences, Beijing, China
3Department of Medical Oncology, Xiamen University, Xiamen, China
4Department of Neurosurgery and Department of Neuroscience, Xiamen University, Xiamen, China
5Medical Isotope Research Center, Peking University, Beijing, China
Find articles by Fu, H. in: JCI | PubMed | Google Scholar
1Department of Nuclear Medicine and Minnan PET Center, Xiamen University, Xiamen, China
2Key Laboratory of Biomacromolecules, Chinese Academy of Sciences, Beijing, China
3Department of Medical Oncology, Xiamen University, Xiamen, China
4Department of Neurosurgery and Department of Neuroscience, Xiamen University, Xiamen, China
5Medical Isotope Research Center, Peking University, Beijing, China
Find articles by Cai, J. in: JCI | PubMed | Google Scholar
1Department of Nuclear Medicine and Minnan PET Center, Xiamen University, Xiamen, China
2Key Laboratory of Biomacromolecules, Chinese Academy of Sciences, Beijing, China
3Department of Medical Oncology, Xiamen University, Xiamen, China
4Department of Neurosurgery and Department of Neuroscience, Xiamen University, Xiamen, China
5Medical Isotope Research Center, Peking University, Beijing, China
Find articles by Yu, L. in: JCI | PubMed | Google Scholar
1Department of Nuclear Medicine and Minnan PET Center, Xiamen University, Xiamen, China
2Key Laboratory of Biomacromolecules, Chinese Academy of Sciences, Beijing, China
3Department of Medical Oncology, Xiamen University, Xiamen, China
4Department of Neurosurgery and Department of Neuroscience, Xiamen University, Xiamen, China
5Medical Isotope Research Center, Peking University, Beijing, China
Find articles by Zeng, R. in: JCI | PubMed | Google Scholar
1Department of Nuclear Medicine and Minnan PET Center, Xiamen University, Xiamen, China
2Key Laboratory of Biomacromolecules, Chinese Academy of Sciences, Beijing, China
3Department of Medical Oncology, Xiamen University, Xiamen, China
4Department of Neurosurgery and Department of Neuroscience, Xiamen University, Xiamen, China
5Medical Isotope Research Center, Peking University, Beijing, China
Find articles by Sun, L. in: JCI | PubMed | Google Scholar
1Department of Nuclear Medicine and Minnan PET Center, Xiamen University, Xiamen, China
2Key Laboratory of Biomacromolecules, Chinese Academy of Sciences, Beijing, China
3Department of Medical Oncology, Xiamen University, Xiamen, China
4Department of Neurosurgery and Department of Neuroscience, Xiamen University, Xiamen, China
5Medical Isotope Research Center, Peking University, Beijing, China
Find articles by Wu, H. in: JCI | PubMed | Google Scholar
1Department of Nuclear Medicine and Minnan PET Center, Xiamen University, Xiamen, China
2Key Laboratory of Biomacromolecules, Chinese Academy of Sciences, Beijing, China
3Department of Medical Oncology, Xiamen University, Xiamen, China
4Department of Neurosurgery and Department of Neuroscience, Xiamen University, Xiamen, China
5Medical Isotope Research Center, Peking University, Beijing, China
Find articles by Wang, Z. in: JCI | PubMed | Google Scholar
1Department of Nuclear Medicine and Minnan PET Center, Xiamen University, Xiamen, China
2Key Laboratory of Biomacromolecules, Chinese Academy of Sciences, Beijing, China
3Department of Medical Oncology, Xiamen University, Xiamen, China
4Department of Neurosurgery and Department of Neuroscience, Xiamen University, Xiamen, China
5Medical Isotope Research Center, Peking University, Beijing, China
Find articles by Wang, F. in: JCI | PubMed | Google Scholar
Published November 7, 2024 - More info
Background Considering trophoblast cell surface antigen 2 (Trop2) is overexpressed in a wide range of human epithelial cancers, it presents an attractive target for the diagnosis and treatment of multiple types of cancer. Herein, we have developed a Trop2-specific radiotracer, 68Ga-MY6349, and present a prospective, investigator-initiated trial to explore the clinical values of 68Ga-MY6349 PET/CT. Methods In this translational study, 90 patients with 15 types of cancer, who underwent 68Ga-MY6349 PET/CT, were enrolled prospectively. Among them, 78 patients underwent paired 68Ga-MY6349 and 18F-FDG PET/CT, and 12 patients with prostate cancer underwent paired 68Ga-MY6349 and 68Ga-PSMA-11 PET/CT. Results Among the 90 patients across 15 types of cancer, 68Ga-MY6349 uptake in tumors was generally high but heterogeneous, varying among lesions, patients, and cancer types. Trop2 expression level determined by immunohistochemistry was highly correlated with 68Ga-MY6349 uptake at primary and metastatic tumor sites. 68Ga-MY6349 PET/CT showed higher tumor uptake (quantified by SUVmax) than 18F-FDG PET/CT in certain types of cancer, including breast (7.2 vs. 5.4, P < 0.001), prostate (9.2 vs. 3.0, P < 0.001), and thyroid cancers (8.5 vs. 3.7, P < 0.001). When compared with 68Ga-PSMA-11, 68Ga-MY6349 PET/CT exhibited comparable lesion uptake (12.2 vs. 12.5, P = 0.223) but a better tumor-to-background contrast (15.8 vs. 12.2, P < 0.001) for primary and metastatic prostate cancer, allowing visualization of more metastatic lesions. Conclusion 68Ga-MY6349 PET/CT is a non-invasive method for comprehensively assessing Trop2 expression in tumors, which can improve the diagnosis and staging for cancer patients, and aid in the decision-making for Trop2-targeted therapies and advancing personalized treatment.